Wednesday 22 March 2023
18:30 CET (Paris), 17:30 GMT (London), 19:30 EET (Athens)
Prostate cancer is the second most common cancer in men worldwide. Although PSA remains the most used test for screening, the limited specificity and an elevated rate of over diagnosis are a problem. Recently a number of novel biomarkers aiming to increase ability to select patients for biopsy and identify men at risk seem to be promising.
The debate will add some new perspective on the topic giving the audience the understanding of whether to screen, how often and with what.
Prof. Ferdinando Petrazzuoli MD, PhD,
A family doctor in Southern Italy. Member of the WONCA Europe Executive Board,Chair of the EURIPA, and a member of the EGPRN which is a network within WONCA Europe.
Prof. Hendrik Van Poppel, MD, PhD,
former chairman of the Department of Urology at the Katholieke Universiteit (KU) in Leuven, Belgium and now chairman of the European Association of Urology (EAU) Policy Office. He is focused on Onco-urological surgery. He was co-founder and is now Chairman of the Scientific Committee of Europa Uomo.
Prof. John Brandt Brodersen, Md, PhD,
of the Department of Public Health at the University of Copenhagen, Denmark. He is a general practitioner with over thirty years of experience in clinical practice. He works as a professor in the area of prevention, medical screening, over diagnosis, over medicalisation, evidencebased medicine and multi-morbidity at the Centre of Research and Education in General Practice, Department of Public Health, University of Copenhagen and at the Primary Health Care Research Unit, Region Zealand. He is also a visiting professor at the Research Unit for General Practice, UiT The Arctic University of Norway.
For questions please contact: